
Prostate cancer is ranked as the fourth most prevalent cancer commonly diagnosed among males over 40 years of age, according to the WHO Cancer Fact Sheet 2020, and it is additionally a leading cause of cancer mortality among males. The incidence of prostate cancer and mortality varied significantly across the globe. Diagnosis of prostate cancer hinders easier management of cases, and prostate-specific antigen (PSA) use for screening of prostate cancer has poor specificity and sensitivity, thereby yielding overdiagnosis and unnecessary biopsies. Radiologically guided (ultrasound/MRI) prostate biopsy, considered the gold standard, is invasive and can miss a significant number of metastatic cancers. Even though mild, other prostate biopsy complications occur on a large scale, and few severe ones are often recorded. Scientists intensify their search for biomarker(s) for non-invasive diagnosis of prostate cancer using proteomics, metabolomics, genomics, and bioinformatics—urinary biomarkers were uniquely on the lookout. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP) receptor 1 (VPAC1), which is overexpressed (a thousandfold) in prostate cancer at the onset of oncogenesis and is excreted in the urine on tumor cells, is a contender in the prostate cancer biomarker quest. VPAC1 is ubiquitous, expressed by normal and malignant cells, and interwoven in their cell membranes. Therefore, using urine samples limits the possibility of making the wrong diagnosis, since VPAC1 is not normally excreted in the urine. Nevertheless, studying transmembrane receptors is intricate. However, producing monoclonal antibodies against the N-terminal end of VPAC1 can provide a promising target for designing a non-invasive diagnostic assay for early detection of prostate cancer using a urine sample.
Citation: Mansur Aliyu, Ali Akbar Saboor-Yaraghi, Shima Nejati, Behrouz Robat-Jazi. Urinary VPAC1: A potential biomarker in prostate cancer[J]. AIMS Allergy and Immunology, 2022, 6(2): 42-63. doi: 10.3934/Allergy.2022006
[1] | David E. Bernholdt, Mark R. Cianciosa, David L. Green, Kody J.H. Law, Alexander Litvinenko, Jin M. Park . Comparing theory based and higher-order reduced models for fusion simulation data. Big Data and Information Analytics, 2018, 3(2): 41-53. doi: 10.3934/bdia.2018006 |
[2] | Nickson Golooba, Woldegebriel Assefa Woldegerima, Huaiping Zhu . Deep neural networks with application in predicting the spread of avian influenza through disease-informed neural networks. Big Data and Information Analytics, 2025, 9(0): 1-28. doi: 10.3934/bdia.2025001 |
[3] | Marco Tosato, Jianhong Wu . An application of PART to the Football Manager data for players clusters analyses to inform club team formation. Big Data and Information Analytics, 2018, 3(1): 43-54. doi: 10.3934/bdia.2018002 |
[4] | Sayed Mohsin Reza, Md Al Masum Bhuiyan, Nishat Tasnim . A convolution neural network with encoder-decoder applied to the study of Bengali letters classification. Big Data and Information Analytics, 2021, 6(0): 41-55. doi: 10.3934/bdia.2021004 |
[5] | Bill Huajian Yang . Modeling path-dependent state transitions by a recurrent neural network. Big Data and Information Analytics, 2022, 7(0): 1-12. doi: 10.3934/bdia.2022001 |
[6] | Wenxue Huang, Qitian Qiu . Forward Supervised Discretization for Multivariate with Categorical Responses. Big Data and Information Analytics, 2016, 1(2): 217-225. doi: 10.3934/bdia.2016005 |
[7] | Jason Adams, Yumou Qiu, Luis Posadas, Kent Eskridge, George Graef . Phenotypic trait extraction of soybean plants using deep convolutional neural networks with transfer learning. Big Data and Information Analytics, 2021, 6(0): 26-40. doi: 10.3934/bdia.2021003 |
[8] | Dongyang Yang, Wei Xu . Statistical modeling on human microbiome sequencing data. Big Data and Information Analytics, 2019, 4(1): 1-12. doi: 10.3934/bdia.2019001 |
[9] | Bill Huajian Yang, Jenny Yang, Haoji Yang . Modeling portfolio loss by interval distributions. Big Data and Information Analytics, 2020, 5(1): 1-13. doi: 10.3934/bdia.2020001 |
[10] | Ugo Avila-Ponce de León, Ángel G. C. Pérez, Eric Avila-Vales . A data driven analysis and forecast of an SEIARD epidemic model for COVID-19 in Mexico. Big Data and Information Analytics, 2020, 5(1): 14-28. doi: 10.3934/bdia.2020002 |
Prostate cancer is ranked as the fourth most prevalent cancer commonly diagnosed among males over 40 years of age, according to the WHO Cancer Fact Sheet 2020, and it is additionally a leading cause of cancer mortality among males. The incidence of prostate cancer and mortality varied significantly across the globe. Diagnosis of prostate cancer hinders easier management of cases, and prostate-specific antigen (PSA) use for screening of prostate cancer has poor specificity and sensitivity, thereby yielding overdiagnosis and unnecessary biopsies. Radiologically guided (ultrasound/MRI) prostate biopsy, considered the gold standard, is invasive and can miss a significant number of metastatic cancers. Even though mild, other prostate biopsy complications occur on a large scale, and few severe ones are often recorded. Scientists intensify their search for biomarker(s) for non-invasive diagnosis of prostate cancer using proteomics, metabolomics, genomics, and bioinformatics—urinary biomarkers were uniquely on the lookout. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP) receptor 1 (VPAC1), which is overexpressed (a thousandfold) in prostate cancer at the onset of oncogenesis and is excreted in the urine on tumor cells, is a contender in the prostate cancer biomarker quest. VPAC1 is ubiquitous, expressed by normal and malignant cells, and interwoven in their cell membranes. Therefore, using urine samples limits the possibility of making the wrong diagnosis, since VPAC1 is not normally excreted in the urine. Nevertheless, studying transmembrane receptors is intricate. However, producing monoclonal antibodies against the N-terminal end of VPAC1 can provide a promising target for designing a non-invasive diagnostic assay for early detection of prostate cancer using a urine sample.
prostate-specific antigen;
vasoactive intestinal peptide;
pituitary adenylate cyclase-activating peptide;
VIP/PACAP receptor 1;
age-standardized rate;
benign prostatic hypertrophy;
5α-dihydrotestosterone;
quantitative reverse transcription polymerase chain reaction;
magnetic resonance imaging;
multiparametric MRI;
dynamic contrast-enhanced MRI;
diffusion-weighted imaging MRI;
trans-rectal ultrasound scan;
enzyme-linked immunosorbent assay;
prostate cancer antigen 3;
transmembrane protease serine 2;
glutathione S-transferase P1;
digital rectal examination;
area under the curve;
hepatocyte growth factor;
insulin-like growth factor binding protein 3;
Plasma osteopontin;
lymph node carcinoma of the prostate;
G protein-coupled receptors;
receptor activity modifying proteins;
seven-transmembrane domain;
extracellular domain;
Chinese hamster ovary;
TATA-box binding protein;
cyclooxygenase-2;
metalloproteinase 9;
urokinase plasminogen activator;
uPA receptor;
4,6-diamidino-2-phenylindole;
adenylyl cyclase;
cAMP response element-binding protein;
phosphokinase A;
inducible nitric oxide synthase;
CREB binding protein;
nuclear factor-κβ;
extracellular signal-regulated kinase;
MAP/ERK kinase (MEK) kinase 1;
IFN regulatory factor-1;
inhibitory κβ kinase;
bombesin-like peptides;
gastrin-releasing peptide receptor;
phospholipase C;
diacylglycerol;
1,4,5-triphosphate;
protein kinase C;
mitogen-activated protein kinase;
mitogen-activated protein kinase kinase;
ETS like-1 protein;
serum response element
With the rapid development of big data and artificial intelligence, data-driven predictions now permeate nearly every aspect of modern science [1,2]. Regression analysis, a key component of data-driven science, has wide applications across various domains, including new material design, stock prediction, medical diagnosis, and geological exploration, etc. [3,4,5,6,7,8,9]. Besides, machine learning offers numerous methods for regression analysis, such as support vector regression (SVR), decision trees (DTs), multi-layer perceptrons (MLPs), deep neural networks, etc. Although those methods can achieve high accuracy, the "black box" nature of neural networks limits their interpretability.
According to the Weierstrass approximation theorem, continuous functions defined on closed intervals can be uniformly approximated by polynomial functions [10]. Moreover, a polynomial function has a simpler form compared to other complex functions, making polynomial regression a natural choice for practical applications [11,12]. Polynomial regression can be divided into univariate function fitting and multi-variate function regression. While univariate function fitting is highly effective supported by popular data analysis software such as Origin, MATLAB, and SPSS based on the least squares algorithm, there remains a lack of fast, effective, and stable algorithms for multivariate function regression.
The theme of this paper is to design a fast, efficient and accurate algorithm to solve the multivariate polynomial regression problems (Eq (1.1)).
y=f(x1,x2,⋯,xn)=n∑i=1αixβii+n∑j,k=1,j≠kγjkxμjjxνkk+n∑s,p,q=1,s≠p≠qηspqxσssxλppxτqq+⋯ | (1.1) |
In the regression process, SVR introduces a kernel function to construct the nonlinear relation. The MLP method employs the weighted summation of variables (∑iωjixi+θj) to achieve the aggregation of information. As the weighted summation only passes a linear relationship between variables, the nonlinear knowledge, for example the product relation xμjjxνkk, should be approximated by using an activation function, such as the sigmoid function, f(x)=1/(1+e−x), the tanh function, f(x)=(ex−e−x)/(ex+e−x), etc. However, the applications of kernel functions in SVR and activation functions in MLPs make it difficult to interpret the machine learning model.
Recently, Kolmogorov-Arnold networks (KANs) have gained attention due to their superior accuracy and interpretability compared to multi-layer perceptrons [13]. MLPs have fixed activation functions on nodes while KANs have learnable activation functions on edges. The Kolmogorov-Arnold representation theorem established that, if f is a multivariate continuous function on a bounded domain, then f can be written as a finite composition of continuous functions of a single variable and the binary operation of addition. The regression model of KANs is in the form of
y=f(x1,x2,⋯,xn)=nL−1∑iL−1=1ϕL−1,iL,iL−1(nL−2∑iL−2=1ϕL−2,iL−1,iL−2⋯(n2∑i2=1ϕ2,i3,i2(n1∑i1=1ϕ1,i2,i1)(n∑i0=1ϕ0,i1,i0(xi0)))) | (1.2) |
where, L represents the number of network layers and ϕk,ik+1,ik is a continuous functions of signal variable. That is to say, KANs train and select suitable signal variable continuous functions in each network layer from the given basic function library including polynomial functions, exponential functions, logarithmic functions, etc. Although, KANs have higher accuracy and interpretability, the regression of product relation in multivariate polynomial functions still need to transform to the coupling of univariate functions, which will undoubtedly increase the complexity of the regression.
The traditional artificial neural network uses nodes whose information transmission is via a sigma unit, i.e., a linear weighted sum of inputs, a=∑iωixi. A pi unit is constructed by replacing the weighted summation in the activation with a weighted product, a=∏ixωii. Units of this type are also designated "higher order" in that they contain polynomial terms of order greater than one (linear). The simplest way of modeling such a product relation in multivariate polynomial functions is to increase the complexity of the node by a pi unit. Moreover, a sigma-pi unit can formulate a sum of product terms,
y=m∑j=1cjaj=m∑j=1cjn∏i=1xωjii. | (1.3) |
Inspired by this architecture of a sigma-pi unit, we find the high-order sigma-pi neural network (SPNN) [14,15] can efficiently achieve the regression of multivariate polynomial functions. The coefficients and exponents of the multivariate polynomial can be determined through the trained neural network weight parameters (cj and ωji).
Performing the regression of multivariate polynomial functions by SPNN has the following advantages compared with that of MLPs and KANs.
● Polynomial regression by the SPNN model has better interpretability than that of MLPs, due to the fact that high-order terms are generated by pi units instead of complex activation functions.
● Polynomial regression by the SPNN model has faster learning efficiency compared with that of KANs, owing to the application of a fixed activation function in polynomial form.
● The optimization and control of the parameters in the SPNN model are more convenient than that in MLPs and KANs. Besides, the forms of the SPNN model are more friendly to real applications.
In an MLP neural network, information from different input signals is transmitted through weighted summation. For example, in a two-layer forward neural network (see Figure 1(a)), the hidden layer
hi=σ1(n∑j=1αijxj+bi), | (2.1) |
and the output signal
y=σ2(m∑i=1βihi+θ), | (2.2) |
where σ1 is the activation function of the hidden layer, σ2 is the activation function of the output layer, α is the weight of the first layer network, β is the weight of the second layer network, and b and θ are the biases. The information transmission from xj to hi, and from hi to y, are all by weighted summation. So, this kind of structure unit in MLP neural networks can be called sigma-sigma units.
To embed high-order coupled information into a neural network, high-order neural networks are designed. For instance, the sigma-pi neural network (SPNN) enables the embedding of product information into the network. In SPNN, the hidden layer
gi=σ1(n∏j=1xαijj+bi), | (2.3) |
and the output layer
y=σ2(m∑i=1βigi+θ). | (2.4) |
The information transmission from xj to gi is by weighted product, and from gi to y is by weighted summation, see Figure 1(b).
As previously mentioned, the basic unit of SPNN is the power function of input signals. We aim to achieve multivariate polynomial regression using the explainable SPNN. In this model, if the activation functions, σ1 and σ2, are linear, the output signal
y=m∑i=1βigi+θ=m∑i=1βi(n∏j=1xαijj+bi)+θ=m∑i=1βi(n∏j=1xαijj)+m∑i=1βibi+θ. | (2.5) |
Cleary, Eq (2.5) is a multivariate polynomial function, where βi is the polynomial coefficient, αij is the polynomial exponent, and ∑mi=1βibi+θ is the constant term. Thus, this explainable SPNN is essentially a type of Kolmogorov-Arnold network.
To illustrate the regression process of a multivariate polynomial function more clearly, we present a simple regression problem as an example:
y=f(x1,x2,⋯,xn)= a1xb11+a2xb22+⋯+anxbnn+n∑i,j=1,i≠jcijxpiixqjj. | (2.6) |
Here, {x1,x2,⋯,xn} represents the state variables, and y is the target variable. Since Eq (2.6) lacks a constant term, bias parameters are not used in the designed network. A two-layer SPNN is employed to solve this regression problem. The number of neurons in the input layer equals n, while the hidden layer contains n+n(n−1)=n2 neurons. The neural connections from the input layer to the hidden layer primarily capture the regression of power functions, such as xbii and xpiixqjj, corresponding to each term in the polynomial function. The network then performs a weighted summation of all terms from the hidden layer to the output layer.
Additionally, to accelerate the parameter optimization, we convert the above sigma-pi neural network to the sigma-sigma neural network, and use the back-propagation algorithm to update the parameters. The input signals are first transformed using logarithmic functions,
xi⇒ui={log(xi),xi>0;−∞,xi=0;log(−xi),xi<0. | (2.7) |
Next, a sigma unit operates on the ui,
vj=n∑i=1αjiui=n∑i=1log(|xi|αji). | (2.8) |
Here αji represents the weight from the ith neuron in the input layer to the jth neuron in the hidden layer. A signed exponential function is then applied to vj,
hj=sig(xi)exp(vj)=sig(xi)exp(n∑i=1log(|xi|αji))=n∏i=1xαjii. | (2.9) |
Therefore, the conversion from the pi unit to the sigma unit can be achieved using logarithmic and exponential operators. The output signal, y, is then obtained by the sigma unit from the hidden layer to the output layer.
y=m∑j=1βjhj=m∑j=1βjn∏i=1xαjii=m∑j=1βjsig(xi)exp(n∑i=1αjilog(|xi|)). | (2.10) |
Here, βj is the weight from the jth neuron in the hidden layer to the output signal. The model error is defined as
Err=12(y−ˆy)2, | (2.11) |
where y is the model output and ˆy is the real value. For parameter updates, the gradient descent method is employed,
βj=βj−ηΔβj,αji=αji−ηΔαji. | (2.12) |
Here, η is the learn rate,
Δβj= ∂Err∂βj= ∂Err∂y∗∂y∂βj= (y−ˆy)∗hj, | (2.13) |
and
Δαji= ∂Err∂αji=∂Err∂vj∗∂vj∂αji= ∂Err∂y∗∂y∂hj∗∂hj∂vj∗∂vj∂αji= (y−ˆy)∗βj∗exp(vj)∗sig(xi)∗log(|xi|). | (2.14) |
The optimized parameters β and α are the corresponding multivariate polynomial regression coefficients and exponents.
The pseudo code of multivariate polynomial regression by our designed neural network is presented in Algorithm 1 below.
Algorithm 1 Multivariate polynomial regression by the explainable sigma-pi neural network |
Inputs: the corresponding multi-variables, x1,x2,⋯,xn, the target variable, y, and the desired multi-variable polynomial form, for example, y=a1xb11+a2xb22+⋯+anxbnn+∑ni,j=1,i≠jcijxpiixqjj.
Outputs: the regression coefficients and exponents, such as, ai,bi,cij,pi,qj. 1: Divide the data into the train set, valid set, and test set. 2: Construct the sigma-pi neural network based on the desired empirical formula. 3: Variable conversion, ui⇐xi. 4: Let the sigma unit work on ui, s.t., ui⇒vj. 5: The signed exponentiation effect on vj, s.t., vj⇒hj. 6: Let the sigma unit work on hj, s.t., hj⇒y, compute the regression error, Err=12(y−ˆy)2, set the error threshold as ε, and define the total epochs as N. 7: while epoch<N do 8: Parameters update, βj=βj−ηΔβj,αji=αji−ηΔαji. 9: if Err<ε then 10: break; 11: output the weight parameters, αji⇒bi,pi,qj and βj⇒ai,cij. 12: else if Err>ε then 13: continue; 14: end if 15: end while |
In this section, we present two examples to demonstrate the feasibility and effectiveness of the proposed model. Moreover, we illustrate the application of our method in analyzing multivariate correlated regression, specifically concerning the maximum stress on concrete pipes under traffic loads.
y=2∗x21∗x2+3∗x31∗x2+4∗x21∗x22. | (3.1) |
In this example, the model is used to determine the regression coefficients and exponents of Eq (3.1) based on generated data. The variable x1 is linearly sampled from the interval [1,3], x2 is randomly sampled from the interval [1,4], and y is calculated according to Eq (3.1). These generated data are briefly presented in Figure 2, where Figure 2(a) gives the time series of x1, x2, and y; Figure 2(b), (c) display scatter plots of y versus x1, and y versus x2, respectively.
The number of neurons in the hidden layer equals 3, i.e., the number of terms of polynomial function Eq (3.1). Let u=log(x1),v=log(x2), and the signals u and v are fed into the sigma unit as inputs. It should be noted that the variables x1 and x2 in this example are restricted to positive values. We use the linear activation function in each architecture, thus, the neurons in the hidden layer satisfy
h1= α11u+α12v=log(xα111)+log(xα122),h2= α21u+α22v=log(xα211)+log(xα222),h3= α31u+α32v=log(xα311)+log(xα322). |
So, by the exponential operation,
eh1= elog(xα111)+log(xα122)=xα111∗xα122,eh2= elog(xα211)+log(xα222)=xα211∗xα222,eh3= elog(xα311)+log(xα322)=xα311∗xα322. |
The output signal is the weighted sum of eh1,eh2, and eh3 according to the sigma unit from the hidden layer to the output layer.
y=β1eh1+β2eh2+β3eh3=β1xα111∗xα122+β2xα211∗xα222+β3xα311∗xα322. |
Here, βi represents the corresponding polynomial regression coefficient, and αij denotes the related polynomial regression exponent. Since we are addressing an integer-order polynomial regression problem, the parameters αij are constrained to integer values during the parameter iteration process. The training is conducted for 500 epochs, with a maximum learning rate of 0.01. Compared with other optimizers, such as BGD, SGD, and MBGD, the combination of the Adam optimizer with a one-cycle scheduler has faster convergence speed and better modeling performance, so we chose this optimization algorithm in the training process. The regression performance is evaluated using the mean squared error (MSE) and the coefficient of determination (R2),
MSE=1nn∑i=1(yi−^yi)2,R2=1−∑ni=1(yi−^yi)2∑ni=1(yi−ˉy)2. |
Here, yi is the real value, ^yi is the regression value, and ˉy is the mean value of y. The modeling results are shown in Figure 3, the train loss and valid loss are depicted by the MSE, and the coefficient of determination R2=1.0.
The weight parameters of the proposed neural network are listed in Table 1. The parameter αij is related to the polynomial exponent, and parameter βi corresponds to the polynomial coefficient.
Parameters | α11 | α12 | α21 | α22 | α31 | α32 | β1 | β2 | β3 |
Values | 2 | 1 | 3 | 1 | 2 | 2 | 2.0 | 3.0 | 4.0 |
From the results above, it is evident that our designed SPNN effectively solves the integer-order multivariate polynomial regression problem. The coefficients and exponents of the integer-order multivariate polynomial function align with the weight parameters of the designed SPNN. In the next example, we use the SPNN to solve a fractional-order multivariate polynomial regression problem.
y=2∗x2.21∗x1.52+3∗x3.41∗x1.02+4∗x2.81∗x2.02. | (3.2) |
In this example, we use the designed SPNN to solve the fractional-order polynomial regression problem. The values of x1 and x2 are generated in the same manner as in Example 1, and the output signal is computed according to Eq (3.3). The dataset contains 3000 samples, and the training is conducted for 10,000 epochs. The Adam optimizer is employed combined with a one-cycle scheduler. The maximum learning rate is set to 0.009, while the optimizer's learning rate is initialized at 0.004. The corresponding time series are plotted in Figure 4(a), and the regression result is shown in Figure 4(b).
The values of mean squared error (MSE), coefficient of determination (R2), and corresponding weight parameters are listed in Table 2.
Parameters | MSE | R2 | α11 | α12 | α21 | α22 | α31 | α32 | β1 | β2 | β3 |
Values | 6.2×10−5 | 1.0 | 2.21 | 1.54 | 2.81 | 2.01 | 3.39 | 1.00 | 2.05 | 3.87 | 3.07 |
Approximation | 2.2 | 1.5 | 2.8 | 2.0 | 3.4 | 1.0 | 2 | 4 | 3 |
From the regression results, we observe small discrepancies between the actual polynomial coefficients (or exponents) and the weight parameters. However, the parameters closely align with the polynomial coefficients and exponents when considering their approximate values. Thus, we conclude that the designed SPNN can effectively solve fractional-order multivariate polynomial regression problems.
In this part, we apply the designed SPNN to analyze the maximum stress of concrete sewage pipelines under the combined influence of traffic load, earth pressure, and groundwater level, with a consideration of 12 physical parameter variables. These variables encompass corrosion depth (Cd), corrosion width (Cw), corrosion length (Cl), void width (Vw), void length (Vl), burial depth (H), traffic load (P), pipe diameter (D), wall thickness (t), bedding modulus (Eb), backfill soil modulus (Es), and groundwater level (hw). The detailed parameter ranges for each variable are provided in Table 3.
Physical variable | Value | Physical variable | Value | ||
Minimum | Maximum | Minimum | Maximum | ||
Cd (cm) | 5 | 90 | P (MPa) | 0.5 | 1.5 |
Cw (°) | 0 | 180 | D (mm) | 300 | 1200 |
Cl (m) | 0 | 10 | t (mm) | 40 | 120 |
Vw (°) | 0 | 120 | Eb (MPa) | 6 | 580 |
Vl (m) | 0 | 3 | Es (MPa) | 5 | 65 |
H (m) | 0.5 | 3 | hw/H | 0.31 | 8.85 |
These physical variables are randomly generated within the specified ranges, resulting in a dataset of 250 samples. The maximum stress signals are formulated by finite element simulation based on these datasets. Figure 5 illustrates the dependence of the maximum stress on each physical variable. As the maximum stress of concrete sewage pipelines is determined by the 12 physical variables, it is challenging to analyze the relationship between individual variables and stress through simple data fitting. As shown in Figure 5, the relationship between maximum stress and each variable is nonlinear and complex, indicating that this is a multivariate nonlinear regression problem. Existing software and algorithms are unable to efficiently and accurately address this challenge; however, our designed SPNN method is capable of handling it effectively.
According to the univariate empirical formula [7,9], we define the multivariate regression equation of the maximum stress as
y= α1Cdβ1+α2Cwβ2+α3Clβ3+α4Vwβ4+α5Vlβ5+α6Hβ6+α7Pβ7+α8Dβ8+α9tβ9+α10Ebβ10+α11Esβ11+α12(hw/H)β12. | (3.3) |
The data set is first normalized to eliminate the influence of dimensionality, and then randomly split into training, validation, and test sets, with respective ratios of 64%, 20%, and 16%. It makes almost no difference to divide the data set at the other ratios, for example, 70%, 15%, and 15%, because of the excellent model performance. The regression model is developed using the explainable SPNN. During the training process, a total of 1000 epochs are set, and the Adam optimizer with with a learning rate equal to 0.006 is employed together with a one-cycle scheduler with the maximum learn rate equal to 0.01. Figure 6(a) shows the training loss and valid loss depicted by MSE, and Figure 6(b) presents a comparison between the real and predicted maximum stress values.
The regression error MSE =3.36×10−5, and the coefficient of determination R2=0.9998. We save model parameters to two decimal places, and the regression equation is
y= 0.35Cd0.51+0.24Cw0.32+0.05Cl0.62+0.25Vw0.06+0.28Vl0.38+0.15H0.19+0.92P1.20+0.72D1.16+0.46t1.13+0.37Eb0.24−0.04Es0.63−0.04(hw/H)0.43. | (3.4) |
It should be noted that the values of coefficients and exponents in Eq (3.4) may exhibit minor fluctuations due to the broad feasible region of the solutions. However, the contributions of each physical variable to the maximum stress derived from Eq (3.4) can be well interpreted. It is evident that the corrosion depth, corrosion width, corrosion length, void width, void length, burial depth, traffic load, pipe diameter, wall thickness, and bedding modulus have positive effects on the maximum stress, while the backfill soil modulus and groundwater level exhibit negative effects. These findings align with existing empirical knowledge.
Additionally, the SHAP approach [16,17,18] is utilized to analyze the impact of input features on the model's output. The SHAP value for each sample (x) corresponding to feature (fi) is computed using Eq (3.5).
SHAPfi(x)=∑fi∈f[|f|×(F|f|)]−1×[Pf(x)−Pf∖fi(x)], | (3.5) |
where fi represents the ith feature (i.e., the ith physical variable), F is the total number of features, and f is a feature subset that includes fi. |f| denotes the number of elements in subset f, and (F|f|) is the number of combinations of F items taken |f| at a time. Pf(x) is the predicted value when all the physical variables in f are selected, and Pf∖fi(x) is the predicted value with all the variables in f except fi. The SHAP values for the samples related to each physical variable are shown in Figure 7.
In Figure 7, if the higher feature value corresponds to larger SHAP values, it indicates a positive effect of that feature on the model output. Conversely, if the higher feature value results in smaller SHAP values, it suggests a negative effect. Thus, we conclude that features P,D,t,Cd,Vl,Eb,Cw,Cl,H, and Vw have a positive effect on the maximum stress, while Es and hw/H have a negative effect. These conclusions align with the regression analysis results from Eq (3.4). Additionally, the importance ranking of the input features is P>D>t>Cd>Vl>Eb>Cw>Cl>H>Vw>Es>hw/H.
According to the regression results, we can further analyze the evolution of the maximum stress of concrete sewage pipelines with respect to the univariate input. By selecting a sample data point and employing the control variable method, the maximum stress signal can be calculated using Eq (3.4), with only one variable being varied. Figure 8 shows the evolution of maximum stress with respect to each physical variable. These univariate evolutionary trends provide theoretical guidance for strategies aimed at repairing and improving the properties of concrete sewage pipelines.
In this manuscript, we propose an explainable sigma-pi neural network to address the multi-variable nonlinear polynomial regression problem. The coefficient and exponent parameters of polynomials are effectively represented by the corresponding weight parameters in the SPNN. To accelerate the regression process, the back-propagation algorithm is employed for parameter optimization. The examples reveal that our designed SPNN can efficiently and accurately solve both integer-order and fractional-order multivariate polynomial regression problems. In practical application, the SPNN provides high-precision fitting of the maximum stress in concrete sewage pipelines under the combined influence of 12 physical parameter variables. Furthermore, feature importance ranking and additional analyses on the relationship between maximum stress and these variables can be conducted based on this explainable machine learning model.
Building upon the framework for solving multi-variable polynomial regression, future algorithms for addressing more complex nonlinear regression problems could be developed through higher-order neural networks, such as sigma-pi or sigma-pi-sigma networks. This study lays the theoretical foundation for developing generalized tools to solve multi-variable nonlinear regression problems.
The authors declare that this manuscript is the authors' original work, and they have not used Artificial Intelligence (AI) tools in the creation of this article.
This work was supported by the China Postdoctoral Science Foundation Funded Project (Grant No. 2022M712902), the Natural Science Foundation of Henan (Grant No. 232300421345), and the Zhongyuan Youth Top Talent Plan (Zhongyuan Youth Postdoctoral Innovative Talents).
The authors declare no conflict of interest with respect to the research, authorship, and/or publication of this article.
[1] |
Kimura T, Egawa S (2018) Epidemiology of prostate cancer in Asian countries. Int J Urol 25: 524-531. https://doi.org/10.1111/iju.13593 ![]() |
[2] |
Pernar CH, Ebot EM, Wilson KM, et al. (2018) The epidemiology of prostate cancer. Cold Spring Harbor Perspect Med 8: a030361-a030380. https://doi.org/10.1101/cshperspect.a030361 ![]() |
[3] |
Adeloye D, David RA, Aderemi AV, et al. (2016) An estimate of the incidence of prostate cancer in Africa: A systematic review and meta-analysis. PLoS One 11: e0153496. https://doi.org/10.1371/journal.pone.0153496 ![]() |
[4] |
Kang DY, Li HJ (2015) The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis. Medicine 94: e410-e418. https://doi.org/10.1097/MD.0000000000000410 ![]() |
[5] |
Ferlay J, Colombet M, Soerjomataram I, et al. (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144: 1941-1953. https://doi.org/10.1002/ijc.31937 ![]() |
[6] | (2018) World Health OrganisationCancer Fact Sheets.WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer |
[7] |
Taitt HE (2018) Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health 12: 1807-1823. https://doi.org/10.1177/1557988318798279 ![]() |
[8] |
Campi R, Brookman-May SD, Subiela Henriquez JD, et al. (2018) Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: A systematic review by the European Association of Urology Section of Oncological Urology. Eur Urol Focus 5: 1029-1057. https://doi.org/10.1016/j.euf.2018.04.001 ![]() |
[9] |
Miah S, Catto J (2014) BPH and prostate cancer risk. Indian J Urol 30: 214-218. https://doi.org/10.4103/0970-1591.126909 ![]() |
[10] |
Fernández-Martínez AB, Bajo AM, Arenas ML, et al. (2010) Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett 299: 11-21. https://doi.org/10.1016/j.canlet.2010.07.019 ![]() |
[11] |
Boyle P, Koechlin A, Bota M, et al. (2016) Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int 118: 731-741. https://doi.org/10.1111/bju.13417 ![]() |
[12] |
Tan ME, Li J, Xu HE, et al. (2015) Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36: 3-23. https://doi.org/10.1038/aps.2014.18 ![]() |
[13] |
Lee YJ, Park JE, Jeon BR, et al. (2013) Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review. Ann Lab Med 33: 233-241. https://doi.org/10.3343/alm.2013.33.4.233 ![]() |
[14] |
Negoita S, Feuer EJ, Mariotto A, et al. (2018) Annual report to the nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer 124: 2801-2814. https://doi.org/10.1002/cncr.31549 ![]() |
[15] |
Zhang K, Aruva MR, Shanthly N, et al. (2008) PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med 49: 112-121. https://doi.org/10.2967/jnumed.107.043703 ![]() |
[16] |
Litwin MS, Tan HJ (2017) The diagnosis and treatment of prostate cancer: a review. JAMA 317: 2532-2542. https://doi.org/10.1001/jama.2017.7248 ![]() |
[17] |
Renard-Penna R, Cancel-Tassin G, Comperat E, et al. (2015) Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. World J Urol 33: 929-936. https://doi.org/10.1007/s00345-015-1570-z ![]() |
[18] |
Ahmed HU, Bosaily ESA, Brown LC, et al. (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389: 815-822. https://doi.org/10.1016/S0140-6736(16)32401-1 ![]() |
[19] | Boesen L (2017) Multiparametric MRI in detection and staging of prostate cancer. Dan Med J 64: B5327. |
[20] | Sosnowski R, Zagrodzka M, Borkowski T (2016) The limitations of multiparametric magnetic resonance imaging also must be borne in mind. Cent Eur J Urol 69: 22-23. https://doi.org/10.5173/ceju.2016.e113 |
[21] |
Saini S (2016) PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol 39: 97-106. https://doi.org/10.1007/s13402-016-0268-6 ![]() |
[22] |
Zhao L, Yu N, Guo T, et al. (2014) Tissue biomarkers for prognosis of prostate cancer: A systematic review and meta-analysis. Cancer Epidem Biomar 23: 1047-1054. https://doi.org/10.1158/1055-9965.EPI-13-0696 ![]() |
[23] |
Jedinak A, Loughlin KR, Moses MA (2018) Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer. Oncotarget 9: 32534-32550. https://doi.org/10.18632/oncotarget.25946 ![]() |
[24] |
Wu D, Ni J, Beretov J, et al. (2017) Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hemat 118: 15-26. https://doi.org/10.1016/j.critrevonc.2017.08.002 ![]() |
[25] |
Tosoian JJ, Ross AE, Sokoll LJ, et al. (2016) Urinary biomarkers for prostate cancer. Urol Clin N Am 43: 17-38. https://doi.org/10.1016/j.ucl.2015.08.003 ![]() |
[26] |
Luo Y, Gou X, Huang P, et al. (2014) The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl 16: 487-492. https://doi.org/10.4103/1008-682X.125390 ![]() |
[27] |
Dijkstra S, Mulders PF, Schalken JA (2014) Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem 47: 889-896. https://doi.org/10.1016/j.clinbiochem.2013.10.023 ![]() |
[28] |
Larsen LK, Jakobsen JS, Abdul-Al A, et al. (2018) Noninvasive detection of high-grade prostate cancer by DNA methylation analysis of urine cells captured by microfiltration. J Uroly 200: 749-757. https://doi.org/10.1016/j.juro.2018.04.067 ![]() |
[29] |
Ratz L, Laible M, Kacprzyk LA, et al. (2017) TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells. Oncotarget 8: 25115-25130. https://doi.org/10.18632/oncotarget.15931 ![]() |
[30] |
Sequeiros T, Bastarós JM, Sánchez M, et al. (2015) Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Prostate 75: 1102-1113. https://doi.org/10.1002/pros.22995 ![]() |
[31] |
Mengual L, Lozano JJ, Ingelmo-Torres M, et al. (2016) Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. BMC Cancer 16: 76. https://doi.org/10.1186/s12885-016-2127-2 ![]() |
[32] |
Fryczkowski M, Bułdak R, Hejmo T, et al. (2018) Circulating levels of omentin, leptin, VEGF, and HGF and their clinical relevance with PSA marker in prostate cancer. Dis Markers 2018: 3852401. https://doi.org/10.1155/2018/3852401 ![]() |
[33] | Dheeraj A, Tailor D, Deep G, et al. (2018) Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) regulates mitochondrial dynamics, EMT, and angiogenesis in progression of prostate cancer. Cancer Res 78: 1095. https://doi.org/10.1158/1538-7445.AM2018-1095 |
[34] | Wisniewski T, Zyromska A, Makarewicz R, et al. (2019) Osteopontin and angiogenic factors as new biomarkers of prostate cancer. Urol J 16: 134-140. |
[35] |
Prager AJ, Peng CR, Lita E, et al. (2013) Urinary aHGF, IGFBP3, and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomarkers Med 7: 831-841. https://doi.org/10.2217/bmm.13.112 ![]() |
[36] |
Rivnyak A, Kiss P, Tamas A, et al. (2018) Review on PACAP-induced transcriptomic and proteomic changes in neuronal development and repair. Int J Mol Sci 19: 1020. https://doi.org/10.3390/ijms19041020 ![]() |
[37] |
Ashina M, Martelletti P (2018) Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?. J Headache Pain 19: 33. https://doi.org/10.1186/s10194-018-0860-4 ![]() |
[38] |
Johnson GC, Parsons R, May V, et al. (2020) The role of pituitary adenylate cyclase-activating polypeptide (PACAP) signaling in the hippocampal dentate gyrus. Front Cell Neurosci 14: 111. https://doi.org/10.3389/fncel.2020.00111 ![]() |
[39] |
Hirabayashi T, Nakamachi T, Shioda S (2018) Discovery of PACAP and its receptors in the brain. J Headache Pain 19: 28. https://doi.org/10.1186/s10194-018-0855-1 ![]() |
[40] |
Leyton J, Coelho T, Coy D, et al. (1998) PACAP (6–38) inhibits the growth of prostate cancer cells. Cancer Lett 125: 131-139. https://doi.org/10.1016/S0304-3835(97)00525-9 ![]() |
[41] |
Derand R, Montoni A, Bulteau-Pignoux L, et al. (2004) Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion. Brit J Pharmacol 141: 698-708. https://doi.org/10.1038/sj.bjp.0705597 ![]() |
[42] |
Couvineau A, Ceraudo E, Tan YV, et al. (2012) The VPAC1 receptor: structure and function of a class B GPCR prototype. Front Endocrinol 3: 139. https://doi.org/10.3389/fendo.2012.00139 ![]() |
[43] |
Couvineau A, Tan YV, Ceraudo E, et al. (2013) Strategies for studying the ligand-binding site of GPCRs: Photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs. Method Enzymol 520: 219-237. https://doi.org/10.1016/B978-0-12-391861-1.00010-1 ![]() |
[44] |
Starr CG, Maderdrut JL, He J, et al. (2018) Pituitary adenylate cyclase-activating polypeptide is a potent broad-spectrum antimicrobial peptide: Structure-activity relationships. Peptides 104: 35-40. https://doi.org/10.1016/j.peptides.2018.04.006 ![]() |
[45] |
Jayawardena D, Guzman G, Gill RK, et al. (2017) Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine. Am J Physiol-Gastr L 313: G16-G25. https://doi.org/10.1152/ajpgi.00081.2017 ![]() |
[46] |
Dorsam GP, Benton K, Failing J, et al. (2011) Vasoactive intestinal peptide signaling axis in human leukemia. World J Biol Chem 2: 146-160. https://doi.org/10.4331/wjbc.v2.i6.146 ![]() |
[47] |
Garcı́a-Fernández MO, Solano RM, Carmena MJ, et al. (2003) Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24: 893-902. https://doi.org/10.1016/S0196-9781(03)00162-1 ![]() |
[48] |
Moretti C, Mammi C, Frajese GV, et al. (2006) PACAP and type I PACAP receptors in human prostate cancer tissue. Ann NY Acad Sci 1070: 440-449. https://doi.org/10.1196/annals.1317.059 ![]() |
[49] |
Tamas A, Javorhazy A, Reglodi D, et al. (2016) Examination of PACAP-like immunoreactivity in urogenital tumor samples. J Mol Neurosci 59: 177-183. https://doi.org/10.1007/s12031-015-0652-0 ![]() |
[50] |
Ibrahim H, Barrow P, Foster N (2011) Transcriptional modulation by VIP: a rational target against inflammatory disease. Clin Epigenet 2: 213-222. https://doi.org/10.1007/s13148-011-0036-4 ![]() |
[51] |
Gomariz RP, Juarranz Y, Carrión M, et al. (2019) An overview of VPAC receptors in rheumatoid arthritis: biological role and clinical significance. Front Endocrinol 10: 729. https://doi.org/10.3389/fendo.2019.00729 ![]() |
[52] |
Couvineau A, Laburthe M (2012) VPAC receptors: structure, molecular pharmacology, and interaction with accessory proteins. Brit J Pharmacol 166: 42-50. https://doi.org/10.1111/j.1476-5381.2011.01676.x ![]() |
[53] |
Tripathi S, Trabulsi EJ, Gomella L, et al. (2016) VPAC1 targeted (64)Cu-TP3805 positron emission tomography imaging of prostate cancer: preliminary evaluation in man. Urology 88: 111-118. https://doi.org/10.1016/j.urology.2015.10.012 ![]() |
[54] |
Arms L, Vizzard MA (2011) Neuropeptides in lower urinary tract function. Handbook of Experimental Pharmacology : 395-423. https://doi.org/10.1007/978-3-642-16499-6_19 ![]() |
[55] |
Inbal U, Alexandraki K, Grozinsky-Glasberg S (2018) Gastrointestinal hormones in cancer. Encyclopedia of Endocrine Diseases. Oxford: Academic Press 579-586. https://doi.org/10.1016/B978-0-12-801238-3.95875-6 ![]() |
[56] |
Tang B, Yong X, Xie R, et al. (2014) Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). Int J Oncol 44: 1023-1031. https://doi.org/10.3892/ijo.2014.2276 ![]() |
[57] |
Reubi JC (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues: clinical implications. Ann NY Acad Sci 921: 1-25. https://doi.org/10.1111/j.1749-6632.2000.tb06946.x ![]() |
[58] | Thakur ML (2016) Targeting VPAC1 genomic receptors for optical imaging of lung cancer. Eur J Nucl Med Mol Imaging 43: S662-S663. |
[59] |
Tang B, Wu J, Zhu MX, et al. (2019) VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism. Oncogene 38: 3946-3961. https://doi.org/10.1038/s41388-019-0709-6 ![]() |
[60] |
Truong H, Gomella LG, Thakur ML, et al. (2018) VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen. World J Urol 36: 719-726. https://doi.org/10.1007/s00345-018-2263-1 ![]() |
[61] |
Liu S, Zeng Y, Li Y, et al. (2014) VPAC1 overexpression is associated with poor differentiation in colon cancer. Tumour Biol 35: 6397-6404. https://doi.org/10.1007/s13277-014-1852-x ![]() |
[62] | Tang B, Xie R, Xiao YF, et al. (2017) VIP promotes gastric cancer progression via the VPAC1/TRPV4/Ca2+ signaling pathway. J Dig Dis 152: S836. https://doi.org/10.1016/S0016-5085(17)32886-X |
[63] | Tripathi S, Trabulsi E, Kumar P, et al. (2015) VPAC1 targeted detection of genitourinary cancer: A urinary assay. J Nuclear Med 56: 388. |
[64] |
Delgado M, Pozo D, Ganea D (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249-290. https://doi.org/10.1124/pr.56.2.7 ![]() |
[65] |
Ganea D, Hooper KM, Kong W (2015) The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol 213: 442-452. https://doi.org/10.1111/apha.12427 ![]() |
[66] |
Wu F, Song G, de Graaf C, et al. (2017) Structure and function of peptide-binding G protein-coupled receptors. J Mol Biol 429: 2726-2745. https://doi.org/10.1016/j.jmb.2017.06.022 ![]() |
[67] |
Moody TW (2019) Peptide receptors as cancer drug targets. Ann NY Acad Sci 1455: 141-148. https://doi.org/10.1111/nyas.14100 ![]() |
[68] |
Latek D, Langer I, Krzysko K, et al. (2019) A molecular dynamics study of vasoactive intestinal peptide receptor 1 and the basis of its therapeutic antagonism. Int J Mol Sci 20: 4348-4369. https://doi.org/10.3390/ijms20184348 ![]() |
[69] |
Langer I (2012) Conformational switches in the VPAC1 receptor. Brit J Pharmacol 166: 79-84. https://doi.org/10.1111/j.1476-5381.2011.01616.x ![]() |
[70] |
Santos R, Ursu O, Gaulton A, et al. (2017) A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16: 19-34. https://doi.org/10.1038/nrd.2016.230 ![]() |
[71] |
de Graaf C, Song G, Cao C, et al. (2017) Extending the structural view of class B GPCRs. Trends Biochem Sci 42: 946-960. https://doi.org/10.1016/j.tibs.2017.10.003 ![]() |
[72] |
Solano RM, Langer I, Perret J, et al. (2001) Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction. J Biol Chem 276: 1084-1088. https://doi.org/10.1074/jbc.M007696200 ![]() |
[73] |
Jazayeri A, Doré AS, Lamb D, et al. (2016) Extra-helical binding site of a glucagon receptor antagonist. Nature 533: 274. https://doi.org/10.1038/nature17414 ![]() |
[74] |
Parthier C, Reedtz-Runge S, Rudolph R, et al. (2009) Passing the baton in class B GPCRs: peptide hormone activation via helix induction?. Trends Biochem Sci 34: 303-310. https://doi.org/10.1016/j.tibs.2009.02.004 ![]() |
[75] |
Ceraudo E, Hierso R, Tan YV, et al. (2012) Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB J 26: 2060-2071. https://doi.org/10.1096/fj.11-196444 ![]() |
[76] |
Hutchings CJ, Koglin M, Olson WC, et al. (2017) Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov 16: 787-810. https://doi.org/10.1038/nrd.2017.91 ![]() |
[77] |
Peyrassol X, Laeremans T, Lahura V, et al. (2018) Development by genetic immunization of monovalent antibodies against human vasoactive intestinal peptide receptor 1 (VPAC1), new innovative, and versatile tools to study VPAC1 receptor function. Front Endocrinol 9: 153. https://doi.org/10.3389/fendo.2018.00153 ![]() |
[78] |
Freson K, Peeters K, De Vos R, et al. (2008) PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood 111: 1885-1893. https://doi.org/10.1182/blood-2007-06-098558 ![]() |
[79] |
Hermann RJ, Van der Steen T, Vomhof-Dekrey EE, et al. (2012) Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry. J Immunol Methods 376: 20-31. https://doi.org/10.1016/j.jim.2011.10.009 ![]() |
[80] |
Langlet C, Langer I, Vertongen P, et al. (2005) Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling. J Biol Chem 280: 28034-28043. https://doi.org/10.1074/jbc.M500449200 ![]() |
[81] |
Ramos-Álvarez I, Mantey SA, Nakamura T, et al. (2015) A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists. Peptides 66: 26-42. https://doi.org/10.1016/j.peptides.2015.01.009 ![]() |
[82] |
Van Rampelbergh J, Juarranz MG, Perret J, et al. (2000) Characterization of a novel VPAC1 selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition. Brit J Pharmacol 130: 819-826. https://doi.org/10.1038/sj.bjp.0703384 ![]() |
[83] |
Dickson L, Aramori I, McCulloch J, et al. (2006) A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacol 51: 1086-1098. https://doi.org/10.1016/j.neuropharm.2006.07.017 ![]() |
[84] |
Moody TW, Nuche-Berenguer B, Jensen RT (2016) Vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol 23: 38-47. https://doi.org/10.1097/MED.0000000000000218 ![]() |
[85] |
Moody TW, Chan D, Fahrenkrug J, et al. (2003) Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Design 9: 495-509. https://doi.org/10.2174/1381612033391621 ![]() |
[86] |
Fernández-Martínez AB, Carmena MJ, Bajo AM, et al. (2015) VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells. Cell Signal 27: 236-244. https://doi.org/10.1016/j.cellsig.2014.11.005 ![]() |
[87] |
Iwasaki M, Akiba Y, Kaunitz JD (2019) Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Research 8: 1629-1642. https://doi.org/10.12688/f1000research.18039.1 ![]() |
[88] |
Langer I (2012) Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies. Front Endocrin 3: 129. https://doi.org/10.3389/fendo.2012.00129 ![]() |
[89] |
Harmar AJ, Fahrenkrug J, Gozes I, et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase—activating polypeptide: IUPHAR Review 1. Brit J Pharmacol 166: 4-17. https://doi.org/10.1111/j.1476-5381.2012.01871.x ![]() |
[90] |
Langer I, Robberecht P (2007) Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans 35: 724-728. https://doi.org/10.1042/BST0350724 ![]() |
[91] |
Igarashi H, Fujimori N, Ito T, et al. (2011) Vasoactive intestinal peptide (VIP) and VIP receptors-elucidation of structure and function for therapeutic applications. Int J Clin Med 2: 500-508. https://doi.org/10.4236/ijcm.2011.24084 ![]() |
[92] |
Delgado M, Ganea D (2000) Inhibition of IFN-gamma-induced Janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol 165: 3051-3057. https://doi.org/10.4049/jimmunol.165.6.3051 ![]() |
[93] |
Smalley SGR, Barrow PA, Foster N (2009) Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 157: 225-234. https://doi.org/10.1111/j.1365-2249.2009.03956.x ![]() |
[94] |
Shaywitz AJ, Greenberg ME (1999) CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821-861. https://doi.org/10.1146/annurev.biochem.68.1.821 ![]() |
[95] |
Delgado M, Ganea D (2001) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem 276: 369-380. https://doi.org/10.1074/jbc.M006923200 ![]() |
[96] |
Dickson L, Finlayson K (2009) VPAC and PAC receptors: From ligands to function. Pharmacol Therapeut 121: 294-316. https://doi.org/10.1016/j.pharmthera.2008.11.006 ![]() |
[97] |
Laburthe M, Couvineau A, Tan V (2007) Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology. Peptides 28: 1631-1639. https://doi.org/10.1016/j.peptides.2007.04.026 ![]() |
[98] |
Collado B, Sánchez MG, Díaz-Laviada I, et al. (2005) Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim Biophys Acta Mol Cell Res 1744: 224-233. https://doi.org/10.1016/j.bbamcr.2005.04.009 ![]() |
[99] |
Park MH, Hong JT (2016) Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells 5: 15. https://doi.org/10.3390/cells5020015 ![]() |
[100] |
Grosset AA, Ouellet V, Caron C, et al. (2019) Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Med 16: e1002847. https://doi.org/10.1371/journal.pmed.1002847 ![]() |
[101] |
Staal J, Beyaert R (2018) Inflammation and NF-κB signaling in prostate cancer: mechanisms and clinical implications. Cells 7: 122. https://doi.org/10.3390/cells7090122 ![]() |
[102] |
Thomas-Jardin SE, Dahl H, Nawas AF, et al. (2020) NF-κB signaling promotes castration-resistant prostate cancer initiation and progression. Pharmacol Therapeut 211: 107538. https://doi.org/10.1016/j.pharmthera.2020.107538 ![]() |
[103] |
Jain G, Cronauer MV, Schrader M, et al. (2012) NF-kappaB signaling in prostate cancer: a promising therapeutic target?. World J Urol 30: 303-310. https://doi.org/10.1007/s00345-011-0792-y ![]() |
[104] |
Moreno P, Ramos-Álvarez I, Moody TW, et al. (2016) Bombesin-related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting, and treatment. Expert Opin Ther Targets 20: 1055-1073. https://doi.org/10.1517/14728222.2016.1164694 ![]() |
[105] |
Ramos-Álvarez I, Moreno P, Mantey SA, et al. (2015) Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides 72: 128-144. https://doi.org/10.1016/j.peptides.2015.04.026 ![]() |
[106] |
Baratto L, Jadvar H, Iagaru A (2018) Prostate cancer theranostics targeting gastrin-releasing peptide receptors. Mol Imaging Biol 20: 501-509. https://doi.org/10.1007/s11307-017-1151-1 ![]() |
[107] |
Moody TW, Ramos-Alvarez I, Jensen RT (2018) Neuropeptide G protein-coupled receptors as oncotargets. Front Endocrinol 9: 345-345. https://doi.org/10.3389/fendo.2018.00345 ![]() |
[108] | Dai J, Shen R, Sumitomo M, et al. (2002) Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 8: 2399. |
[109] |
Putney JW, Tomita T (2012) Phospholipase C signaling and calcium influx. Adv Biol Regul 52: 152-164. https://doi.org/10.1016/j.advenzreg.2011.09.005 ![]() |
[110] |
Weber HC (2009) Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol 16: 66-71. https://doi.org/10.1097/MED.0b013e32831cf5aa ![]() |
[111] |
Fujita K, Pavlovich CP, Netto GJ, et al. (2009) Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Hum Pathol 40: 924-933. https://doi.org/10.1016/j.humpath.2009.01.004 ![]() |
[112] |
Fujita K, Nonomura N (2018) Urinary biomarkers of prostate cancer. Int J Urol 25: 770-779. https://doi.org/10.1111/iju.13734 ![]() |
[113] |
Wei JT (2015) Urinary biomarkers for prostate cancer. Curr Opin Urol 25: 77-82. https://doi.org/10.1097/MOU.0000000000000133 ![]() |
[114] |
Trabulsi EJ, Tripathi SK, Gomella L, et al. (2017) Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study. BJU Int 119: 885-895. https://doi.org/10.1111/bju.13775 ![]() |
[115] |
Trabulsi E, Tripathi S, Calvaresi A, et al. (2016) VPAC1 in shed urinary cells—A potential genitourinary cancer biomarker. J Urol 195: e12. https://doi.org/10.1016/j.juro.2016.02.1880 ![]() |
[116] | Hoepel J (2021) Unraveling the mechanisms of antibody-dependent inflammation [PhD's thesis]. University of Amsterdam, Netherlands . |
[117] |
Lagerström MC, Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7: 339-357. https://doi.org/10.1038/nrd2518 ![]() |
[118] |
Pediani JD, Ward RJ, Marsango S, et al. (2018) Spatial intensity distribution analysis: studies of G protein-coupled receptor oligomerisation. Trends Pharmacol Sci 39: 175-186. https://doi.org/10.1016/j.tips.2017.09.001 ![]() |
[119] |
Hutchings CJ, Koglin M, Marshall FH (2010) Therapeutic antibodies directed at G protein-coupled receptors. mAbs 2: 594-606. https://doi.org/10.4161/mabs.2.6.13420 ![]() |
Parameters | α11 | α12 | α21 | α22 | α31 | α32 | β1 | β2 | β3 |
Values | 2 | 1 | 3 | 1 | 2 | 2 | 2.0 | 3.0 | 4.0 |
Parameters | MSE | R2 | α11 | α12 | α21 | α22 | α31 | α32 | β1 | β2 | β3 |
Values | 6.2×10−5 | 1.0 | 2.21 | 1.54 | 2.81 | 2.01 | 3.39 | 1.00 | 2.05 | 3.87 | 3.07 |
Approximation | 2.2 | 1.5 | 2.8 | 2.0 | 3.4 | 1.0 | 2 | 4 | 3 |
Physical variable | Value | Physical variable | Value | ||
Minimum | Maximum | Minimum | Maximum | ||
Cd (cm) | 5 | 90 | P (MPa) | 0.5 | 1.5 |
Cw (°) | 0 | 180 | D (mm) | 300 | 1200 |
Cl (m) | 0 | 10 | t (mm) | 40 | 120 |
Vw (°) | 0 | 120 | Eb (MPa) | 6 | 580 |
Vl (m) | 0 | 3 | Es (MPa) | 5 | 65 |
H (m) | 0.5 | 3 | hw/H | 0.31 | 8.85 |
Parameters | α11 | α12 | α21 | α22 | α31 | α32 | β1 | β2 | β3 |
Values | 2 | 1 | 3 | 1 | 2 | 2 | 2.0 | 3.0 | 4.0 |
Parameters | MSE | R2 | α11 | α12 | α21 | α22 | α31 | α32 | β1 | β2 | β3 |
Values | 6.2×10−5 | 1.0 | 2.21 | 1.54 | 2.81 | 2.01 | 3.39 | 1.00 | 2.05 | 3.87 | 3.07 |
Approximation | 2.2 | 1.5 | 2.8 | 2.0 | 3.4 | 1.0 | 2 | 4 | 3 |
Physical variable | Value | Physical variable | Value | ||
Minimum | Maximum | Minimum | Maximum | ||
Cd (cm) | 5 | 90 | P (MPa) | 0.5 | 1.5 |
Cw (°) | 0 | 180 | D (mm) | 300 | 1200 |
Cl (m) | 0 | 10 | t (mm) | 40 | 120 |
Vw (°) | 0 | 120 | Eb (MPa) | 6 | 580 |
Vl (m) | 0 | 3 | Es (MPa) | 5 | 65 |
H (m) | 0.5 | 3 | hw/H | 0.31 | 8.85 |